15 March 2006 - ULSTER SPIN-OUT LICENSES GIP HORMONE AGONISTS TO AMYLIN

The deal, with a headline value of £23.6 million, kicks off with a “modest” upfront payment that Diabetica says will enable it to continue development of its other main products. A deal with one of the leading companies in novel treatments for diabetes is an important endorsement of Diabetica's science, and sets the company up for a private funding round later this year. MORE>>>

07 March 2006 - DIABETICA ANNOUNCES A DEVELOPMENT LICENCE FOR GIP AGONIST ANTIDIABETIC THERAPEUTICS

Diabetica Limited (Diabetica) (Coleraine, Northern Ireland) today announced a worldwide licensing agreement that provides Amylin Pharmaceuticals, Inc. (Amylin) (San Diego, California) with exclusive rights to Diabetica's intellectual property for the development of GIP Agonists. MORE>>>

07 March 2006 - UUTech CEO WELCOMES DIABETICA WORLDWIDE LICENSING AGREEMENT

Reaction to today's announcement that UU spin-out company Diabetica has signed a worldwide licensing agreement with Amylin Pharmaceuticals, Inc. (Amylin) (San Diego, California) for its groundbreaking diabetes therapy..MORE>>>

07 October 2005 - UU SCIENTISTS DEVELOP DIABETES DRUGS

Ulster scientists are developing innovative drugs that could represent important new therapeutic tools to help ease the burden of diabetes worldwide. The news comes as a UN World Health Organisation report identifies diabetes as one of the major health issues facing the world in the 21st century. “The holy grail of diabetes treatment is safe and effective management of blood glucose. We believe that novel molecules arising from our platform GIP technology should provide effective new tools to help individuals better control diabetes,” Dr McClenaghan said. .MORE>>>

Summer/Autumn 2008 - INTRODUCING THE INCRETIN GANG

When it comes to therapies for Type 2 diabetes, new classes of drugs have been few and far between over the last few decades, until the new kids on the block – derived from a group of hormones called ‘incretins' – burst onto the scene. Professor Flatt has recently shown that blocking the action of GIP under certain circumstances could be useful as a treatment to counter obesity and increase the effectiveness of insulin. “We're now looking at the development of new and long-acting molecules as potential drugs for people with diabetes.” So, both blocking and enhancing the effects of GIP could be of benefit for future treatments for diabetes. MORE>>>

08 April 2008 - AWARDS FOR GROUND-BREAKING ULSTER SCIENTISTS

Professor Flatt was recipient of the Dorothy Hodgkin Lecture Award in recognition of his international contribution to research in the field of diabetes. This is one of Diabetes UK's highest honours in memory of the late Dorothy Crowfoot Hodgkin OM FRS. This award recognizes work “in developing innovative approaches and drugs for treatment of the growing number of people in our community with obesity-associated diabetes”. MORE>>>

15 January 2008 - HIGH HOPES FOR NORTH'S INNOVATORS AS ECONOMIC INDICATORS APPEAR GLOOMY

Do you know whom you have to thank for these potentially life-saving inventions? Northern Ireland. Or more precisely the brilliant minds that hailed from Northern Ireland. There is a wealth of new talent emerging from the North's universities. Spin-out companies such as Fusion Antibodies, which is working on the development of antibody-based drugs for cancer, and Diabetica Limited, which is developing new strategies and products for treating diabetes and obesity, are just two of the exciting companies to watch for. MORE>>>

02 July 2007 - AND THE WINNERS ARE... CHAMBER CELEBRATES OUTSTANDING BUSINESS SUCCESS

Coleraine Borough Chamber of Commerce hosted its second bi-annual Coleraine Borough Business Awards themed around the Chamber's 'Working for a brighter future'. Innovation Award sponsored by Ulster Bank This company has shown continued innovation in their ability to bring unique products to market.  They have developed an international profile and demonstrated commercial viability by linkages with a major US based world leader in their field.  This company needs to be congratulated on their forward thinking approach, driven by high quality research from a dedicated team. The winner was Diabetica Ltd. MORE>>>

Summer 2007 - NEW THERAPEUTICS FOR 'DIABESITY'

UU spin-out company, Diabetica Limited, is developing new therapeutics with which to tackle ‘diabesity', the diabetes and obesity epidemic which represents one of the world's major healthcare and socioeconomic challenges. MORE>>>

02 January 2007 - OUTSTANDING CONTRIBUTIONS TO BUSINESS AND THE COMMUNITY

Dr Neville McClenaghan was awarded the University of Ulster Distinguished Business Fellow for his contributions to translational research focused on the diagnosis, treatment, cure and prevention of diabetes. Dr McClenaghan's expertise in technology transfer, innovation and business development has led to the successful commercialisation of research leading to formation of UU spin-out company Diabetica Ltd. MORE>>>

15 October 2005 - UU ACADEMIC HONOURED FOR CONTRIBUTION TO DIABETES RESEARCH

Professor Peter Flatt, Head of the Diabetes Research Group and CSO of Diabetica awarded the Biochemistry Medal from the Irish Area Section of the Biochemical Society in recognition of ground-breaking research into potential new drugs for the treatment of diabetes. MORE>>>

06 April 2005 - UK ACCOLADE FOR UU DIABETES RESEARCHER

Dr Neville McClenaghan is the recipient of prestigious Physiological Society's Sharpey-Schafer Prize Lecture awarded every three years to a research physiologist, as an endorsement of “scientific standing” and on the basis of “sustained and notable contributions to physiology”. This recognizes Dr McClenaghan's contributions to cellular bioengineering and research which could lead to future innovative therapies of diabetes. MORE>>>